Access to Life-Saving Medicine
Isn’t a Privilege — It’s a Right!
We believe no one should be denied the most promising treatments because manufacturing is too costly or not possible at scale. Yet today, millions of patients are left waiting as life-saving medicines remain out of reach – because of exactly these issues.
We exist to change that. Our mission is to transform the way advanced drugs are made, eliminating wasteful, expensive production methods and ultimately making these breakthrough therapies scalable, sustainable, and accessible for all.
At Ningaloo Biosystems, we’re not just imagining a future where everyone has access to the best medicine — we’re building it!
Transforming How
Advanced Medicines Are Made
Through our pioneering light-based technology, we bring real-time control to bioreactor processes by precisely modulating the activity of production cells. Powered by synthetic biology, our platform empowers biopharma companies to break through productivity barriers and lower prohibitive costs of manufacturing complex biopharmaceuticals.
Because everyone deserves a chance in life — and access to the medicines that make it possible.
Converting Cells into Light-Controlled Machines — Discover the Possibilities
We are Ningaloo
With a unique blend of scientific and industrial know-how and the unwavering grit of true pioneers, our team is ready to transform the way life-saving medicines are delivered to the world.
Hanns-Martin Schmidt
Co-founder & Managing Director
Hanns-Martin has spent 20+ years in research & development as well as startup & entrepreneurship in biotechnology, combined with substantial experience as an industry filmmaker & digital media producer
Herbert Mueller-Hartmann
Co-founder & Managing Director
Herbert is a dynamic life science management and strategy professional with 20+ years of experience from startup to large enterprise environments with a background in the bioprocessing and biotechnology industry
News
Check out the latest news from the Ningaloo world
Optogenetic Gene Control Platform Featured in npj SBA Review
Ningaloo Biosystems’ collaborative optogenetics work has been cited in a review published in npj Systems Biology and Applications, a partner journal of the Nature Portfolio. The citation highlights the growing relevance of light-controlled gene expression as a tool for advancing dynamic regulation in bioproduction.
Dynamic Light Control of Bispecific Antibody Production
Ningaloo Biosystems has released a new white paper presenting advances in its proprietary optogenetic platform. By placing multiple antibody chains under light-inducible control, the platform enables dynamic, tunable assembly of bispecific antibodies, improving product quality and simplifying downstream processing.
Advancing Light-Controlled Gene Expression for Industrial Bioproduction
Ningaloo Biosystems has released a new white paper presenting advances in its proprietary optogenetic platform. By delivering up to 500-fold induction of gene expression in HEK and CHO cells the platform now allows precise, dynamic modulation of production outcomes.
Complete Solutions from R&D to Production
With the possibilities of optogenetic systems to orchestrate and custom tailor gene expression and cellular signaling, Ningaloo Biosystems is developing turnkey solutions consisting of both the biological as well as the optoelectronic components. This will allow you to go way beyond current biotechnology standards.